VNDA May 2024 1.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 11:39AM EDT
| Previous close | 4.0100 |
| Open | 4.0100 |
| Bid | 4.1000 |
| Ask | 4.9000 |
| Strike | 1.00 |
| Expiry date | 2024-05-17 |
| Day's range | 4.0100 - 4.0100 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksVanda (VNDA) Rises on Positive Data From Motion Sickness Study
Vanda's (VNDA) tradipitant appears effective in preventing vomiting associated with motion sickness in a second phase III study. Stock rises on the news.
PR NewswireVanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results from its second Phase III study of tradipitant in motion sickness, confirming the previously reported results of two efficacy studies demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness. This Phase III study was conducted in real-world conditions on boats in the coastal waters of the United States (U.S.).
GuruFocus.comVanda Pharmaceuticals Reports Mixed Q1 2024 Results, Misses Revenue Estimates
Challenges and Strategic Developments Shape the Quarter
© 2024 Yahoo. All rights reserved.